Omeros Corporation (OMER)
NasdaqGM · USD · Healthcare · Biotechnology
$16.80 (+3.13%) as of
Key statistics
- Market cap
- 1.22B
- P/E (TTM)
- 13.77
- Forward P/E
- 13.66
- EPS (TTM)
- 1.22
- Dividend yield
- 0.00%
- 52-week range
- 6.24 – 21.24
- Beta
- 2.57
- Revenue (TTM)
- 38.42M
- Profit margin
- 324.88%
- Analyst target
- $27.50
- Volume
- 133.70k
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seattle, WA, United States
- Employees
- 175
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.